On Tuesday, the U.S. Food and Drug Administration accepted AstraZeneca Plc's (NASDAQ:AZN) New Drug Application (NDA) for baxdrostat for adult patients with hard-to-control (uncontrolled or treatment-resistant) hypertension as an add-on to other antihypertensive medicines.

There are 1.4 billion people worldwide living with hypertension. In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control.

Aldosterone is increasingly recognised as a key driver of hard-to-control hypertension, contributing to elevated cardiovascular and renal risk.

Also Read: AstraZeneca’s Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Data

The NDA is based on data from the BaxHTN Phase 3 trial, which was presented during